Some of our cancer centers are experiencing issues.  View More Important Notifications x
texas oncology more breakthroughs. more victories



First-Line Ribociclib + Letrozole in Patients with De Novo HR+, HER2- Advanced Breast Cancer


Dr. Joyce O’Shaughnessy of Texas Oncology−Baylor Sammons Cancer Center discusses the MONALEESA-2 trial, a Phase III, randomized, double-blind, international study of LEE011 in combination with letrozole vs. letrozole alone, in postmenopausal women with HR+/HER2- advanced breast cancer.

Click here to read the full interview from

Related Physicians

Related Cancer Centers